Studies show the power of real-world oncology evidence to generate insights into treatment effectiveness and patient outcomes

IRVING, Texas, May 13, 2022–(BUSINESS WIRE)–Ontario®, a McKesson focused on vendor technology and oncology research, education and hard evidence, announced the acceptance of seven abstracts for presentation to the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). The world’s leading health economics and outcomes research conference, ISPOR 2022, will take place in Washington, DC, and virtually May 15-18, 2022.

“The acceptance of these studies highlights the critical role that Ontada’s real-world data and evidence solutions play in the ability of our life science partners to accelerate the development and commercialization of oncology therapies.” , said Susan Shiff, Ph.D., president of Ontada. “The studies highlight a wide range of innovative ways to better understand treatment regimens and outcomes. These are essential to support drug development and the progress of new drugs designed to improve patient care.

In an oral abstract session on Tuesday, May 17 from 4:30-5:30 p.m. ET, study results will be presented, “Feasibility of using oncology-specific electronic health record (EHR) data to emulate clinical trial inclusion and exclusion criteria.” Assessing the utility of structured and unstructured data from oncology-specific EHR systems, the study examined oncology clinical trial eligibility criteria to assess the extent to which real-world data can be used to replicate retrospectively the information needed in the trials.

“These results demonstrate that oncology-specific EHR data can be leveraged to mimic clinical trial inclusion and exclusion criteria, providing the opportunity to assess treatment options using controls. outpatients in cases where a randomized clinical trial may not be feasible,” said Nicholas Robert. , MD, study co-author and Ontario’s Chief Medical Officer. “Complementing clinical trials by capturing drug efficacy data with real-world evidence will ultimately improve our understanding of how drugs work in broader patient groups.”

Ontada data scientists and researchers leveraged our real-world data and analytics capabilities in additional poster studies to be showcased at this year’s ISPOR:

The full schedule of presentations, including timing and author information, can be found here. For more information or to interview a trial investigator, contact Ryan Mathre at 651.335.2338 or [email protected]

About Ontario

Ontario® is a real-world oncology data and evidence, clinical education and provider technology company dedicated to transforming the fight against cancer. Part of McKesson Corporation, we support science through our data, technology and channels, which accelerate innovation for life science companies, support the education of community oncology providers and advance patient care. Together with our partners, we improve the lives of cancer patients. For more information, visit or follow @OntadaOncology.

See the source version on


General and economic press
Ryan Mathre, External Communications
651.335.2338 [email protected]